Neupogen and filgrastim biosimilars (appendix: regimens and risk factors)
This document appendix lists chemotherapy regimens associated with intermediate/high febrile neutropenia risk, patient risk factors, and references relevant to Neupogen and filgrastim biosimilars for oncology patients; it informs coverage/administration considerations for Neighborhood Health Plan of Rhode Island members receiving myeloid growth factors.
No material clinical or coverage changes in this revision.
Coverage Criteria and Appendices
Regimens associated with intermediate/high FN risk
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.